Navigation Links
Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
Date:6/18/2008

ration. Dr. Katz served on the executive committee of the Optic Neuritis Treatment Trial, and has been an active participant and principle investigator of many multi-centre clinical trials.

Dr. Katz currently serves as Clinical Professor of Ophthalmology at New York University School of Medicine as well as at the Weill Medical College of Cornell University. Dr. Katz served as a fellow at Harvard University in Boston, the National Institutes of Health, The National Hospital at Queen's Square in London, and the University of California at San Francisco after completing residencies in Neurology at Harvard Medical School and in Ophthalmology at Tufts-New England Medical Center. He received his MD with honors from the Case Western Reserve University School of Medicine and his AB, magna cum laude, from Colgate University. He is the author of several hundred publications, and the recipient of over two dozen major research grants.

About Danube Pharmaceuticals, Inc.

Danube is a biopharmaceutical company dedicated to the research and development of treatments for diseases of the eye. Danube's lead compound DNB-001, is a small molecule for the treatment of glaucoma available in both oral and topical formulation. In preclinical studies DNB-001 has been shown through novel mechanisms of action to both lower intraocular pressure (IOP) and to provide direct neuroprotective benefits to the optic nerve and its retinal ganglion cells, providing a dual approach to glaucoma therapy not provided by any currently marketed product. DNB-001 has been tested in a Phase I clinical trial in Europe and is currently being studied in a Phase II clinical trial in Europe. For more information on Danube please visit http://www.danubepharma.com .

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from antic
'/>"/>

SOURCE Danube Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
2. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
3. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
4. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
5. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners
8. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
9. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... Industry Analysis, Size, Share, Growth, Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is a ... RNA) into cells. This technology helps the cells to ... metabolism by affecting the nuclear genes. The transfection technology ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... 2014 Understanding the need for better ... and the gap that currently exists in this area, ... industry-leading portfolio of validated ion channel and GPCR cell ... lines, as ion channels control many critical physiological functions ... creates the potential to treat a variety of human ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Fla., Dec. 6, 2010 Investigators report no evidence of ... in a gene therapy trial using a vector under development ... (University College London) to correct the inherited bleeding disorder. ... test, with low and intermediate doses of the vector expected ...
... 6, 2010 See video from Novartis at: ... Novartis announced 24-month data showing that Tasigna® (nilotinib) ... of adult patients with newly diagnosed Philadelphia chromosome-positive ... These new data, from the first Phase III ...
... Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: ... follow up results from the Company,s pivotal phase III ... Company,s recent Marketing Authorization Application (the "MAA") currently under ... The end-of-study results showed continued improvement in the trial,s ...
Cached Biology Technology:Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 2Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 3Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 2New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 3New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 5New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 6
(Date:7/10/2014)... -- Smart technology emphasis grows in biometrics sector ... NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: AAPL ), Visa Inc. (NYSE: ... (OTCQB: NXTD) a biometric authentication company focused on the growing ... of 30 second spots on CNBC for its next generation ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... According to the new market ... Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application ... & Finance), and Geography - Global Trends & Forecasts ... Fingerprint Sensors Market is projected to cross $14.35 Billion ... from 2014 to 2020. Browse more than ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... with atrial fibrillation are often treated with anticoagulants to ... dose and patients have to have their blood tested ... of Gothenburg and Chalmers University of Technology have now ... risk assessments. Atrial fibrillation, or irregular heartbeat, ...
... day of competition in London, a team of four ... emerged as the winners of this year,s Biotechnology Young ... Biotechnology Young Entrepreneurs Scheme (YES) competition are Ben Owens, ... University of Oxford. The team pitched their ...
... industry is booming more and more solar modules ... plants are increasingly feeding power into the grid. Multi-junction ... can achieve efficiencies of up to 43 percent - ... crystalline silicon. The trick: they consist of several semi-conductor ...
Cached Biology News:New method for safer dosing of anticoagulants 2Winning early-career researchers excel in entrepreneurship 2Winning early-career researchers excel in entrepreneurship 3Fraunhofer researchers receive the Franco-German Business Award 2011 2
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
...
Biology Products: